Application of tangent-arc technology for deep inspiration breath-hold radiotherapy in left-sided breast cancer
ObjectiveTo explore the advantages of dosimetry and the treatment efficiency of tangent-arc technology in deep inspiration breath-hold radiotherapy for breast cancer.MethodsForty patients with left-sided breast cancer who were treated in our hospital from May 2020 to June 2021 were randomly selected...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1145332/full |
| _version_ | 1797682366305533952 |
|---|---|
| author | Yucheng Li Wenming Zhan Yongshi Jia Hanchu Xiong Baihua Lin Qiang Li Huaxin Liu Lingyun Qiu Yinghao Zhang Jieni Ding Chao Fu Weijun Chen |
| author_facet | Yucheng Li Wenming Zhan Yongshi Jia Hanchu Xiong Baihua Lin Qiang Li Huaxin Liu Lingyun Qiu Yinghao Zhang Jieni Ding Chao Fu Weijun Chen |
| author_sort | Yucheng Li |
| collection | DOAJ |
| description | ObjectiveTo explore the advantages of dosimetry and the treatment efficiency of tangent-arc technology in deep inspiration breath-hold radiotherapy for breast cancer.MethodsForty patients with left-sided breast cancer who were treated in our hospital from May 2020 to June 2021 were randomly selected and divided into two groups. The first group’s plan was a continuous semi-arc that started at 145° ( ± 5°) and stopped at 325° ( ± 5°). The other group’s plan, defined as the tangent-arc plan, had two arcs: the first arc started at 145° ( ± 5°) and stopped at 85° ( ± 5°), and the second arc started at 25° ( ± 5°) and stopped at 325° ( ± 5°). We compared the target dose, dose in organs at risk (OARs), and treatment time between the two groups.ResultsThe target dose was similar between the continuous semiarc and tangent-arc groups. The V5 of the right lung was significantly different between the two groups (Dif 5.52, 95% confidence interval 1.92-9.13, t=3.10, P=0.004), with the patients in the continuous semi-arc and tangent-arc groups having lung V5 values of (9.16 ± 1.62)%, and (3.64 ± 0.73)%, respectively. The maximum dose to the spinal cord was (1835.88 ± 222.17) cGy in the continuous semi-arc group and (599.42 ± 153.91) cGy in the tangent-arc group, yielding a significant difference between the two groups (Dif 1236.46, 95% confidence interval 689.32-1783.6, t=4.57, P<0.001). The treatment times was (311.70 ± 60.45) s for patients in the continuous semi-arc group and (254.66 ± 40.73) s for patients in the tangent-arc group, and there was a significant difference in the mean number of treatment times between the two groups (Dif 57.04, 95% confidence interval 24.05-90.03, t=3.5, P=0.001).ConclusionBoth the continuous semi-arc and tangent-arc plans met the clinical prescription dose requirements. The OARs received less radiation with the tangent-arc plan than the continuous semi-arc plan, especially for the lung (measured as V5) and the spinal cord (measured as the maximum dose). Tangent-arc plan took significantly less time than the continuous semi-arc, which can greatly improve treatment efficiency. Therefore, tangent-arc plans are superior continuous semi-arc plans for all cases. |
| first_indexed | 2024-03-11T23:58:39Z |
| format | Article |
| id | doaj.art-f276206bc8c340f7aeb30ddb10086323 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T23:58:39Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f276206bc8c340f7aeb30ddb100863232023-09-18T07:01:29ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-08-011310.3389/fonc.2023.11453321145332Application of tangent-arc technology for deep inspiration breath-hold radiotherapy in left-sided breast cancerYucheng Li0Wenming Zhan1Yongshi Jia2Hanchu Xiong3Baihua Lin4Qiang Li5Huaxin Liu6Lingyun Qiu7Yinghao Zhang8Jieni Ding9Chao Fu10Weijun Chen11Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaCancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaCancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaCancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaCancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaCancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaCancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaCancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaCancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaCancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaDepartment of Tumor Radiochemotherapy, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaCancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaObjectiveTo explore the advantages of dosimetry and the treatment efficiency of tangent-arc technology in deep inspiration breath-hold radiotherapy for breast cancer.MethodsForty patients with left-sided breast cancer who were treated in our hospital from May 2020 to June 2021 were randomly selected and divided into two groups. The first group’s plan was a continuous semi-arc that started at 145° ( ± 5°) and stopped at 325° ( ± 5°). The other group’s plan, defined as the tangent-arc plan, had two arcs: the first arc started at 145° ( ± 5°) and stopped at 85° ( ± 5°), and the second arc started at 25° ( ± 5°) and stopped at 325° ( ± 5°). We compared the target dose, dose in organs at risk (OARs), and treatment time between the two groups.ResultsThe target dose was similar between the continuous semiarc and tangent-arc groups. The V5 of the right lung was significantly different between the two groups (Dif 5.52, 95% confidence interval 1.92-9.13, t=3.10, P=0.004), with the patients in the continuous semi-arc and tangent-arc groups having lung V5 values of (9.16 ± 1.62)%, and (3.64 ± 0.73)%, respectively. The maximum dose to the spinal cord was (1835.88 ± 222.17) cGy in the continuous semi-arc group and (599.42 ± 153.91) cGy in the tangent-arc group, yielding a significant difference between the two groups (Dif 1236.46, 95% confidence interval 689.32-1783.6, t=4.57, P<0.001). The treatment times was (311.70 ± 60.45) s for patients in the continuous semi-arc group and (254.66 ± 40.73) s for patients in the tangent-arc group, and there was a significant difference in the mean number of treatment times between the two groups (Dif 57.04, 95% confidence interval 24.05-90.03, t=3.5, P=0.001).ConclusionBoth the continuous semi-arc and tangent-arc plans met the clinical prescription dose requirements. The OARs received less radiation with the tangent-arc plan than the continuous semi-arc plan, especially for the lung (measured as V5) and the spinal cord (measured as the maximum dose). Tangent-arc plan took significantly less time than the continuous semi-arc, which can greatly improve treatment efficiency. Therefore, tangent-arc plans are superior continuous semi-arc plans for all cases.https://www.frontiersin.org/articles/10.3389/fonc.2023.1145332/fulldeep inspiration breath-holdleft breast cancerdosimetryorgan of riskcontinuous semi-arctangent-arc |
| spellingShingle | Yucheng Li Wenming Zhan Yongshi Jia Hanchu Xiong Baihua Lin Qiang Li Huaxin Liu Lingyun Qiu Yinghao Zhang Jieni Ding Chao Fu Weijun Chen Application of tangent-arc technology for deep inspiration breath-hold radiotherapy in left-sided breast cancer Frontiers in Oncology deep inspiration breath-hold left breast cancer dosimetry organ of risk continuous semi-arc tangent-arc |
| title | Application of tangent-arc technology for deep inspiration breath-hold radiotherapy in left-sided breast cancer |
| title_full | Application of tangent-arc technology for deep inspiration breath-hold radiotherapy in left-sided breast cancer |
| title_fullStr | Application of tangent-arc technology for deep inspiration breath-hold radiotherapy in left-sided breast cancer |
| title_full_unstemmed | Application of tangent-arc technology for deep inspiration breath-hold radiotherapy in left-sided breast cancer |
| title_short | Application of tangent-arc technology for deep inspiration breath-hold radiotherapy in left-sided breast cancer |
| title_sort | application of tangent arc technology for deep inspiration breath hold radiotherapy in left sided breast cancer |
| topic | deep inspiration breath-hold left breast cancer dosimetry organ of risk continuous semi-arc tangent-arc |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1145332/full |
| work_keys_str_mv | AT yuchengli applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer AT wenmingzhan applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer AT yongshijia applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer AT hanchuxiong applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer AT baihualin applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer AT qiangli applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer AT huaxinliu applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer AT lingyunqiu applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer AT yinghaozhang applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer AT jieniding applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer AT chaofu applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer AT weijunchen applicationoftangentarctechnologyfordeepinspirationbreathholdradiotherapyinleftsidedbreastcancer |